- Home
- ATYR vs SOR Comparison
ATYR vs SOR Comparison
Compare ATYR & SOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- SOR
- Stock Information
- Founded
- ATYR 2005
- SOR 1968
- Country
- ATYR United States
- SOR United States
- Employees
- ATYR N/A
- SOR N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- SOR Investment Managers
- Sector
- ATYR Health Care
- SOR Finance
- Exchange
- ATYR Nasdaq
- SOR Nasdaq
- Market Cap
- ATYR 327.0M
- SOR 348.7M
- IPO Year
- ATYR 2015
- SOR N/A
- Fundamental
- Price
- ATYR $2.96
- SOR $41.72
- Analyst Decision
- ATYR Strong Buy
- SOR
- Analyst Count
- ATYR 6
- SOR 0
- Target Price
- ATYR $18.60
- SOR N/A
- AVG Volume (30 Days)
- ATYR 1.5M
- SOR 16.2K
- Earning Date
- ATYR 03-13-2025
- SOR 01-01-0001
- Dividend Yield
- ATYR N/A
- SOR 7.24%
- EPS Growth
- ATYR N/A
- SOR N/A
- EPS
- ATYR N/A
- SOR 6.50
- Revenue
- ATYR $235,000.00
- SOR N/A
- Revenue This Year
- ATYR $1,387.23
- SOR N/A
- Revenue Next Year
- ATYR $873.22
- SOR N/A
- P/E Ratio
- ATYR N/A
- SOR $6.41
- Revenue Growth
- ATYR N/A
- SOR N/A
- 52 Week Low
- ATYR $1.42
- SOR $36.41
- 52 Week High
- ATYR $4.66
- SOR $42.75
- Technical
- Relative Strength Index (RSI)
- ATYR 37.05
- SOR 46.64
- Support Level
- ATYR $3.20
- SOR $41.27
- Resistance Level
- ATYR $3.94
- SOR $41.93
- Average True Range (ATR)
- ATYR 0.25
- SOR 0.78
- MACD
- ATYR -0.08
- SOR 0.03
- Stochastic Oscillator
- ATYR 9.33
- SOR 32.93
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.